Latest / Stock Movers / Standard Chartered Rises, Stellantis Gains, GSK Falls
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios.
- 0:04Speaker 2: Podcasts.
- 0:05Speaker 3: Radio. News.
- 0:08Speaker 1: The Stock Movers Report. Your roundup of companies making moves
- 0:12Speaker 1: in the stock market. Harnessing the power of Bloomberg data.
- 0:16Speaker 2: Let's take a look at some of the stocks on
- 0:18Speaker 2: the move today in Europe. I'm Tiwa Adebayo with Caroline Hepka.
- 0:21Speaker 2: And we're joined by Bloomberg reporter Josh Quint-Warner. So, Josh,
- 0:25Speaker 2: we're looking at European bank earnings. We've heard from a
- 0:27Speaker 2: slew of names, the likes of BNP Paribas, UBS. But
- 0:31Speaker 2: is Standard Chartered keeping up with its peers?
- 0:34Speaker 3: It certainly appears to be coming out on top this morning.
- 0:37Speaker 3: It's the best performer in the sector. It's up about 3.5%
- 0:40Speaker 3: at the moment, and that's following the strong gains that
- 0:43Speaker 3: we saw booked in Hong Kong overnight. You know, profit
- 0:47Speaker 3: rose by about 29% in the latest quarter. That topped
- 0:50Speaker 3: estimates and was driven by record net inflows into its
- 0:53Speaker 3: wealth unit and some robust trading activity. The wealth unit,
- 0:57Speaker 3: for example, lured a record $ 20 billion in net new money,
- 1:00Speaker 3: and flow trading income was also 21% higher. You know,
- 1:04Speaker 3: that strong performance has prompted it to lift its outlook
- 1:06Speaker 3: for the year. Operating income will grow more than previously
- 1:10Speaker 3: expected and return on tangible equity will reach about 14%
- 1:13Speaker 3: up from its prior goal of more than 12%. As
- 1:16Speaker 3: a result, we're seeing shares having their best day in
- 1:18Speaker 3: three months. That's extending a rebound following a period of
- 1:22Speaker 3: pressure since the stock hit all-time highs about a month ago.
- 1:26Speaker 3: Just flicking at some of the other bank earnings this morning,
- 1:29Speaker 3: Deutsche Bank is also performing well, up about 3%. after
- 1:32Speaker 3: beating US peers on fixed income trading revenue, while Santander
- 1:37Speaker 3: and UBS are the ones that are down about 2%
- 1:39Speaker 3: to 3% after failing to impress.
- 1:42Speaker 2: Okay.
- 1:43Speaker 1: So, those are the banks. What about the carmaker, Solantis?
- 1:47Speaker 1: What do we know about the turnaround? Yeah.
- 1:49Speaker 3: So, the Italian carmaker reported profits ahead of expectations this
- 1:53Speaker 3: morning and confirmed its guidance for the year. That's providing
- 1:57Speaker 3: a bounce after Stellantis shares hit an all-time low last week.
- 2:01Speaker 3: The intact outlook is being welcomed. We've seen guidance cuts
- 2:04Speaker 3: from several carmakers, especially in Germany. We saw Mercedes-Benz do
- 2:08Speaker 3: that just this week. In terms of negatives for Stellantis,
- 2:12Speaker 3: it booked losses in Europe as it struggles to compete
- 2:14Speaker 3: with Chinese brands. And industrial free cash flow was still
- 2:18Speaker 3: pretty much in the negative territory. But it is still
- 2:21Speaker 3: planning with its turnaround plan to deliver a positive free
- 2:23Speaker 3: cash flow next year. And also, earnings turned positive in
- 2:27Speaker 3: North America after introducing new models. So, some green shoots.
- 2:31Speaker 3: But today, it's more a relief bounce than anything. Shares
- 2:34Speaker 3: are still down 60% since the start of this year.
- 2:37Speaker 3: And that makes it the worst performer in the automotive
- 2:39Speaker 3: space in Europe.
- 2:41Speaker 1: Interesting.
- 2:41Speaker 2: So, that's the latest on the automotive space. But lastly,
- 2:44Speaker 2: we want to talk about pharmaceuticals. GSK slumping this morning.
- 2:49Speaker 2: What is all of that about?
- 2:51Speaker 3: Yeah, quite a hefty move. Down about 4%. That's its
- 2:54Speaker 3: worst day in about six months. What's weighing on the
- 2:58Speaker 3: stock is a slump in vaccine sales and also an
- 3:01Speaker 3: adjustment to guidance. So, profit rose 3% in the last quarter,
- 3:06Speaker 3: but that was driven more by legacy products like its
- 3:08Speaker 3: asthma drugs. But sales of vaccines like its blockbuster Shingle shot, Shingrix,
- 3:14Speaker 3: were down. Bloomberg Intelligence's John Murphy said the weak vaccine's
- 3:18Speaker 3: performance will raise questions over the growth outlook for its
- 3:21Speaker 3: drugs going forward. He suggested one of its drugs, Orexv,
- 3:25Speaker 3: might be facing more intense competition and that sales might
- 3:29Speaker 3: have even peaked for Shingrix. And the reason that's a
- 3:31Speaker 3: concern is because vaccines account for about 28% of sales
- 3:35Speaker 3: this year and is expected to drive about a third
- 3:37Speaker 3: of sales growth over the coming years. You know, GSK
- 3:41Speaker 3: also said it now expects to hit the lower half
- 3:43Speaker 3: of its guided profit growth this year. And so, that
- 3:48Speaker 3: is reversing some of the gains booked leading into the print.
- 3:53Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:57Speaker 1: us throughout the day for the latest roundup of companies
- 3:59Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:04Speaker 1: listen to Bloomberg Radio live. Catch us on YouTube, Bloomberg.com,
- 4:08Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:11Speaker 1: Business app.